x

Posted 28 July, 2023

Salona Global Medical Device Corp appointed Michael Seckler as new CEO

OTC:LNDZF appointed new Chief Executive Officer Michael Seckler in a 8-K filed on 28 July, 2023.


  On July 24, 2023, Salona Global Medical Device Corporation (the "Company") appointed Michael Seckler, 58, to the position of Chief Executive Officer.  

Don't how to trade CEO change? Read Reasons for CEO Turnover and Effect on Stock Performance.
Overview of Salona Global Medical Device Corp
Health Care/Life Sciences • Medical Equipment/Supplies
Evome Medical Technologies, Inc. engages in the provision of financial and consultancy services to the mental health and addiction industry. It operates through the Medical Billing and Financial Services segments. The Medical Billing segment focuses on its customers in United States. The Financial Services segment offers asset based financial services to healthcare providers in the United States. The company was founded by Robert Munro on September 17, 2013 and is headquartered in Shirley, NY.
Market Cap
$5.84M
View Company Details
Salona Global Medical Device Corp by TradingView
Relevant filing section
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On July 24, 2023, Salona Global Medical Device Corporation (the "Company") appointed Michael Seckler, 58, to the position of Chief Executive Officer. From June 13, 2023 through July 24, 2023, Mr. Seckler served as Interim Chief Executive Officer of the Company. From October 2022 through May 2023, Mr. Seckler served as Chief Operating Officer and from January 2020 through September 2022, Mr. Seckler served as Senior Vice President of FerGene, a gene therapy company affiliated with Ferring International Center, SA, a Swiss multinational biopharmaceutical company ("Ferring"). From January 2017 through December 2019, Mr. Seckler was Vice President of Global Marketing and Corporate Communications at Ferring.

In connection with Mr. Seckler's appointment as Chief Executive Officer, he will be paid an annual salary of US$100,000 and variable compensation based on incentives of up to US$200,000 annually. Additionally, he has been granted options under the Company's 2021 Amended and Restated Stock Option Plan to purchase up to 750,000 common shares of the Company vesting equally over a three-year period, with a term of five years and an exercise price per share of CAD$0.29. In connection with Mr. Seckler's prior appointment as Interim Chief Executive Officer he was granted options under the Company's 2021 Amended and Restated Stock Option Plan to acquire an aggregate of 250,000 common shares of the Company, vesting equally over a three-year period, with a term of five years and an exercise price per share of CAD$0.25. The options and underlying shares for both grants are subject to a four month and one day hold period commencing on the date of grant pursuant to the policies of the TSX Venture Exchange. In addition, Mr. Seckler continues to be eligible to participate in the benefit programs generally available to executive officers of the Company.

There are no arrangements or understandings between Mr. Seckler and any other persons pursuant to which he was selected as Chief Executive Officer. There are also no family relationships between Mr. Seckler and any director or executive officer of the Company and he has no direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.